At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 66 enrolled
Drug / intervention
GB002 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1A Single Ascending Dose and Multiple Ascending Dose Double-Blind, Placebo-Controlled, Randomized Trial of Oral Inhalation PK10571 in Healthy Adult Subjects
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.·interventional·Posted Mar 22, 2018·Updated Jun 9, 2020
In Brief
A Phase 1 clinical trial evaluating GB002, Generic Dry Powder Inhaler, and 1 other intervention for Safety Issues. Completed, enrolled 66 participants across 1 site.
Detailed Summary
This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSafety Issues
CountriesUnited States
CollaboratorsPulmokine Inc., Worldwide Clinical Trials
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedMar 2018
Primary CompletionDec 2018
TodayJul 2026
First PostedMar 22, 2018
Enrollment StartSep 6, 2017
Primary CompletionDec 3, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.3 years ago
Interventions
GB002drug
Inhaled GB002
Generic Dry Powder Inhalerdevice
dry powder inhaler used for inhalation of active drug or placebo
Placebodrug
Inhaled placebo